A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

A new study found that GLP-1 weight-loss drugs with the active ingredient liraglutide can significantly reduce migraines.

Novo Nordisk has introduced Wegovy, a once-weekly weight-loss injection, in India. The drug aims to manage obesity and reduce ...

“Beyond weight loss, Wegovy has shown cardiovascular benefits such as reducing the risk of major adverse cardiovascular events in obese or overweight patients with heart disease,” says Dr. Emch.

People considering weight-loss medications might wonder which one works best, and first-of-its-kind research points to an answer. A new study published in the New England Journal of Medicine ...

If insurance doesn’t cover Ozempic or Wegovy for weight loss, the average monthly price is $1,430, according to Drugs.com. People may need to stop due to side effects, cost or health issues.

Wegovy (semaglutide) is an FDA-approved medication for chronic weight management. Learn more about Wegovy, including how it works and potential risks.